The use of selective Janus kinase inhibitor upadacitinib in a patient with psoriatic arthritis (clinical observation)
Year: 2025
Type: article
Study design: Case Report
Abstract: We describe a patient with psoriatic arthritis (PSA) and palmoplantar psoriasis, resistant to standard therapy, who observed a significant decrease in disease activity on the background of upadacitinib at a dose of 15 mg/day. Remission was achieved by the 3rd month of treatment. No adverse phenomena were observed within 6 months of treatment.
Source: Modern Rheumatology Journal
Author: Yu. A. Lushpaeva
Institution: Ministry of Health of the Russian Federation
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4409678654